[Research Progress in the Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Drugs Targeting Spike Protein]

Jia-Yi Geng; Hao Sun; Qiang Ni; Qiu-Yu Li

doi:10.3881/j.issn.1000-503X.15002

[Research Progress in the Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Drugs Targeting Spike Protein]

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2022 Dec;44(6):1056-1062. doi: 10.3881/j.issn.1000-503X.15002.

[Article in Chinese]

Authors

Jia-Yi Geng¹, Hao Sun¹, Qiang Ni¹, Qiu-Yu Li¹

Affiliation

¹ Department of Respiratory and Critical Care Medicine,Peking University Third Hospital,Beijing 100191,China.

PMID: 36373644
DOI: 10.3881/j.issn.1000-503X.15002

Abstract

The coronavirus disease 2019(COVID-19) caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) is spreading around the world,while the specific drugs targeting SARS-CoV-2 are still under development.On the basis of the biological characteristics of SARS-CoV-2 and the key protein(spike protein) for viral replication,this paper introduces the research progress in the action sites of related drugs,providing information for clinical application and ideas for development of anti-SARS-CoV-2 drugs.

Keywords: Chinese medicine; glycosylation; inhibitor; severe acute respiratory syndrome coronavirus 2; spike protein.

Publication types

English Abstract

MeSH terms

COVID-19*
Humans
SARS-CoV-2* / metabolism
Spike Glycoprotein, Coronavirus / metabolism

Substances

spike protein, SARS-CoV-2
Spike Glycoprotein, Coronavirus